Gossamer Bio, Inc. (NASDAQ:GOSS) Stock Has Average Target Price of $256.00

Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) have been given a consensus rating of “Hold” by the ten ratings firms that are presently covering the company, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and five have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $246.40.

A number of brokerages have recently weighed in on GOSS. Wall Street Zen cut Gossamer Bio from a “hold” rating to a “sell” rating in a research report on Sunday, September 20th. Wedbush lowered their price objective on Gossamer Bio to $32.00 and set a “neutral” rating for the company in a research note on Wednesday. HC Wainwright reaffirmed a “buy” rating on shares of Gossamer Bio in a research report on Thursday, August 27th. Weiss Ratings lowered shares of Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, November 4th. Finally, Chardan Capital reissued a “buy” rating on shares of Gossamer Bio in a research note on Monday, October 26th.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in GOSS. GSA Capital Partners LLP purchased a new position in Gossamer Bio during the 2nd quarter worth approximately $2,467,000. Kalehua Capital Management LLC purchased a new stake in shares of Gossamer Bio in the first quarter valued at $3,363,000. ARCH Venture Management LLC purchased a new stake in shares of Gossamer Bio in the second quarter valued at $1,326,004. BlackRock Inc. acquired a new stake in shares of Gossamer Bio in the second quarter worth $1,262,000. Finally, Corient Private Wealth LP acquired a new stake in shares of Gossamer Bio in the second quarter worth $926,000. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio Trading Down 2.4%

Shares of GOSS opened at $10.97 on Monday. The stock has a 50 day moving average of $10.56 and a 200-day moving average of $32.93. Gossamer Bio has a 52 week low of $8.29 and a 52 week high of $309.60.

Gossamer Bio (NASDAQ:GOSS) last released its earnings results on Tuesday, November 10th. The company reported ($7.36) earnings per share for the quarter, missing the consensus estimate of ($3.79) by ($3.57). The business had revenue of $38.43 million for the quarter, compared to analysts’ expectations of $12.16 million. Analysts expect that Gossamer Bio will post -27.13 earnings per share for the current fiscal year.

About Gossamer Bio

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing medicines for diseases with significant unmet medical needs. The company concentrates primarily on immunology, inflammation and pulmonary disorders. Its lead product candidate is seralutinib, an inhaled tyrosine kinase inhibitor designed to target pathways involving platelet-derived growth factor, colony-stimulating factor 1 and stem cell factor receptors. Gossamer is developing seralutinib for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.